Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3

Min Qiu,Zachary Glass,Jinjin Chen,Mary Haas,Xin Jin,Xuewei Zhao,Xuehui Rui,Zhongfeng Ye,Yamin Li,Feng Zhang,Qiaobing Xu
DOI: https://doi.org/10.1073/pnas.2020401118
IF: 11.1
2021-03-01
Proceedings of the National Academy of Sciences
Abstract:Significance Genome editing technologies enable the permanent repair of disease-causing genetic mutations. However, the application of this technology has been limited by the technical challenge of achieving safe, effective, and specific in vivo delivery of the CRISPR-Cas9 genome editing components. Here, we report the development of a newly identified lipid nanoparticle (LNP) for specific delivery of CRISPR-Cas9 mRNA to the liver. While LNPs have been FDA approved for delivery of siRNA to the liver, here we examine their application for genome editing. When compared head-to-head, our delivery platform significantly outperforms the FDA-approved LNP in the efficient delivery of Cas9 mRNA for knockdown of the Angptl3 gene and subsequent regulation of hypercholesterolemia, while matching the safety and specificity of the approved platform.
What problem does this paper attempt to address?